Breath Analysis by Ion Mobility Spectrometry

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by Lung Clinic Hemer
Sponsor:
Information provided by (Responsible Party):
Michael Westhoff MD, Lung Clinic Hemer
ClinicalTrials.gov Identifier:
NCT00632307
First received: February 29, 2008
Last updated: September 1, 2015
Last verified: August 2015

February 29, 2008
September 1, 2015
July 2006
June 2020   (final data collection date for primary outcome measure)
Identification of diseases specific VOCs [ Time Frame: years ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00632307 on ClinicalTrials.gov Archive Site
Change of disease specific VOCs under therapy [ Time Frame: years ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Breath Analysis by Ion Mobility Spectrometry
Detection of Clusters of Volatile Organic Compounds (VOC)in Patients With Different Lung Disorders by Ion Mobility Spectrometry. Different Clusters of VOC in the Diagnosis of Different Lung Disorders Using Ion Mobility Spectrometry

Recognition of disease specific clusters of volatile organic compounds in patients with different lung diseases, using breath analysis with ion mobility spectrometry. Lung diseases of interest are:

  • COPD
  • tumors
  • airway infection
  • interstitial lung disease
  • sleep apnea Hypothesis: Breath analysis with ion mobility spectrometry can differentiate pulmonary disorders.
Recruitment of patients with different lung diseases goes on. First sub-group analysis of patients with COPD,lung cancer and sarcoidosis is done in order to create a training set of VOC-clusters for further validation in a bigger population of patients.
Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
breath, pleural fluid (only in patients with therapeutic pleurocentesis)
Non-Probability Sample
patients of the lung clinic hemer with pulmonary diseases.
Lung Diseases
Not Provided
  • 1
    COPD
  • 2
    lung cancer
  • 3
    airway infection
  • 4
    interstitial lung disease
  • 5
    sleep apnea
  • 6
    pulmonary disorders with pleural infusions
  • 7
    sarcoidosis
  • 8
    healthy persons

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1000
June 2020
June 2020   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Any patient
  • Ages 18-90 years old

Exclusion criteria:

- Patient who are not able to perform an exhalation manoever.

Both
18 Years to 90 Years   (Adult, Senior)
Yes
Contact: Michael Westhoff, MD 004923729082203 michael.westhoff@lkhemer.de
Contact: Patric Litterst, MD 004923729082545 pneumologie@lkhemer.de
Germany
 
NCT00632307
lkhemer1-2008
No
Not Provided
Not Provided
Michael Westhoff MD, Lung Clinic Hemer
Lung Clinic Hemer
Not Provided
Principal Investigator: Michael Westhoff, MD Lung Clinic Hemer, 58675 Hemer, Germany
Lung Clinic Hemer
August 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP